The EU-funded REACTION project has received CE marking for their GlucoTab device. The GlucoTab, a mobile system for blood glucose management, can now be used for diabetes patients outside of clinical trials.

"This is a big milestone that has been achieved within the REACTION consortium", says project coordinator Dr. Lukas Schaupp (University of Graz). "We're very happy to see tangible outcomes of our extensive work."

The GlucoTab is a mobile decision support system system for healthcare professionals supporting blood glucose management of hospitalized patients with type 2 diabetes.

Main benefits:

  • The average blood glucose was reduced by up to 20% compared to standard care;
  • The percentage of blood glucose measurements in target range was higher than in best-practice clinical trials without increasing the number of hypoglycemic events;
  • The GlucoTab was well accepted and constantly in use during the clinical studies, and the adherence with the GlucoTab dose recommendations was generally very high;
  • Nurses, who are the main users of the GlucoTab, perceived the system as a relief and felt safe in using it.

With the CE label, the GlucoTab device can now be used in all hospitals and not only during clinical studies.

The REACTION project will end in February 2014.